SCHEMBL379685

SCHEMBL379685

Brc1csc2ccnc(NCc3ccco3)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.47
ALDH1A1 P00352 7/20 0.47
TSHR P16473 5/20 0.47
MAPK1 P28482 4/20 0.47
KMT2A Q03164 4/20 0.47
MAPT P10636 4/20 0.47
MEN1 O00255 3/20 0.47
POLB P06746 3/20 0.47
ALOX15 P16050 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
ESR1 P03372 1/20 0.47
ESR2 Q92731 1/20 0.47
HTT P42858 6/20 0.46
LMNA P02545 5/20 0.46
HPGD P15428 4/20 0.46
NOD2 Q9HC29 1/20 0.46
KDM4E B2RXH2 4/20 0.45
HSD17B10 Q99714 2/20 0.45
BLM P54132 1/20 0.45
REN P00797 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379745 0.83 EED (0.49) SMN1; SMN2ALDH1A1TSHRMAPK1KMT2A
SCHEMBL379852 0.80 UTS2R (0.54) SMN1; SMN2ALDH1A1TSHRMAPK1KMT2A
SCHEMBL379640 0.80 MAPT (0.53) SMN1; SMN2ALDH1A1TSHRMAPK1KMT2A
SCHEMBL379790 0.80 KDM4E (0.52) SMN1; SMN2ALDH1A1TSHRMAPK1KMT2A
SCHEMBL379904 0.80 UTS2R (0.49) SMN1; SMN2ALDH1A1TSHRMAPK1ESR1
SCHEMBL379503 0.77 TNF (0.50) SMN1; SMN2ALDH1A1TSHRMAPK1MAPT
SCHEMBL380352 0.75 HSD17B10 (0.48) SMN1; SMN2ALDH1A1TSHRMAPK1KMT2A
SCHEMBL379470 0.74 IGF1R (0.42) SMN1; SMN2ALDH1A1KMT2AMAPTMEN1
SCHEMBL379638 0.71 TUBB4A (0.44) KMT2AMAPTMEN1KDRL3MBTL1
SCHEMBL380611 0.69 HPGD (0.43) TSHRLMNAHPGDHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 SMN1; SMN2 1651/4885ALDH1A1 371/4885TSHR 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.